Part D Formulary Edits: CMS Focus On Covering All Labeled Uses Unwarranted, PCMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacy benefit managers express alarm that CMS is shifting on its definition of a medically-accepted indication for Medicare drug coverage.
You may also be interested in...
Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated
A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication
Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated
A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication
Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits
The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes